1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine is a chemical compound, often referred to as **PFMP**. While I can't provide medical or research advice, I can tell you that this compound is likely important for research because it is a **potent and selective inhibitor of the enzyme monoamine oxidase B (MAO-B)**.
**Here's why this is significant:**
* **MAO-B and Neurodegenerative Diseases:** MAO-B is an enzyme that breaks down neurotransmitters like dopamine. It's believed that excessive MAO-B activity can contribute to the development of neurodegenerative diseases like Parkinson's disease.
* **Potential Therapeutic Uses:** Inhibiting MAO-B with drugs like PFMP could potentially slow down the progression of these diseases by increasing dopamine levels in the brain.
**Important Note:** PFMP is a research chemical and is not currently approved for therapeutic use. It's crucial to remember that:
* Research chemicals should only be handled by qualified professionals in controlled laboratory settings.
* The safety and effectiveness of PFMP for treating any medical condition have not been established.
If you are interested in learning more about PFMP, I encourage you to consult with a qualified healthcare professional or research scientist.
1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: selective sigma-1 receptor ligand; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128032 |
| CHEMBL ID | 417001 |
| SCHEMBL ID | 3913603 |
| MeSH ID | M0276572 |
| Synonym |
|---|
| CHEMBL417001 , |
| bdbm50058017 |
| 4-[1-(3-fluoro-propyl)-piperidin-4-ylmethoxy]-benzonitrile |
| 4-[[1-(3-fluoropropyl)piperidin-4-yl]methoxy]benzonitrile |
| 1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine |
| benzonitrile, 4-((1-(3-fluoropropyl)-4-piperidinyl)methoxy)- |
| 4-((1-(3-fluoropropyl)-4-piperidinyl)methoxy)benzonitrile |
| 180847-28-3 |
| dvg774j9lj , |
| 1-fpr-4-cnphomep |
| unii-dvg774j9lj |
| SCHEMBL3913603 |
| DTXSID40171021 |
| 1-(3-fluoropropyl)-4-[(4-cyanophenoxy)methyl]piperidine |
| 4-((1-(3-(fluoro)propyl)-4-piperidinyl)methoxy)benzonitrile |
| Excerpt | Reference | Relevance |
|---|---|---|
| "0 mug per intravenous injection, based on the combined no observable adverse effect levels (NOAEL, mg/m(2)) measured in these species." | ( Preclinical acute toxicity studies and dosimetry estimates of the novel sigma-1 receptor radiotracer, [18F]SFE. Chang, RC; Mirsalis, JC; Ng, H; Schindler-Horvat, J; Stabin, MG; Waterhouse, RN; Zhao, J, ) | 0.13 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.6518 | 10.0000 | AID63985 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.0043 | 0.0000 | 0.4901 | 10.0000 | AID630410 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0043 | 0.0003 | 0.2671 | 5.0700 | AID204796 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| dopamine neurotransmitter receptor activity, coupled via Gi/Go | D(2) dopamine receptor | Homo sapiens (human) |
| G-protein alpha-subunit binding | D(2) dopamine receptor | Homo sapiens (human) |
| protein binding | D(2) dopamine receptor | Homo sapiens (human) |
| heterotrimeric G-protein binding | D(2) dopamine receptor | Homo sapiens (human) |
| dopamine binding | D(2) dopamine receptor | Homo sapiens (human) |
| ionotropic glutamate receptor binding | D(2) dopamine receptor | Homo sapiens (human) |
| identical protein binding | D(2) dopamine receptor | Homo sapiens (human) |
| heterocyclic compound binding | D(2) dopamine receptor | Homo sapiens (human) |
| G protein-coupled receptor activity | D(2) dopamine receptor | Homo sapiens (human) |
| G protein-coupled opioid receptor activity | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| protein binding | Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||